Healios K.K. (HLOSF)
USD 1.35
(0.0%)
USD 1.35
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 108 Million JPY | 20.0% |
| 2022 | 90 Million JPY | 119.51% |
| 2021 | 40.99 Million JPY | 51.85% |
| 2020 | 26.99 Million JPY | 14571.12% |
| 2019 | 184.03 Thousand JPY | 100.24% |
| 2018 | -78 Million JPY | -2.67% |
| 2017 | -75.96 Million JPY | 24.65% |
| 2016 | -100.81 Million JPY | -16136.31% |
| 2015 | -620.92 Thousand JPY | -100.27% |
| 2014 | 230.76 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 430 Million JPY | 782.54% |
| 2024 Q1 | -416.24 Thousand JPY | -178.75% |
| 2023 Q2 | 55.42 Thousand USD | 5.19% |
| 2023 FY | 108 Million JPY | 20.0% |
| 2023 Q4 | 566.95 Thousand USD | 221.03% |
| 2023 Q1 | 52.68 Thousand USD | -99.91% |
| 2023 Q3 | -468.44 Thousand USD | -945.19% |
| 2022 Q2 | 11 Million JPY | 0.0% |
| 2022 Q4 | 60 Million JPY | 650.0% |
| 2022 Q3 | 8 Million JPY | -27.27% |
| 2022 Q1 | 11 Million JPY | 0.0% |
| 2022 FY | 90 Million JPY | 119.51% |
| 2021 FY | 40.99 Million JPY | 51.85% |
| 2021 Q2 | 10 Million JPY | 11.11% |
| 2021 Q4 | 11 Million JPY | 0.0% |
| 2021 Q1 | 8.99 Million JPY | 50.0% |
| 2021 Q3 | 11 Million JPY | 10.0% |
| 2020 Q1 | 7 Million JPY | 0.0% |
| 2020 FY | 26.99 Million JPY | 14571.12% |
| 2020 Q3 | 7 Million JPY | 0.0% |
| 2020 Q2 | 7 Million JPY | 0.0% |
| 2020 Q4 | 6 Million JPY | -14.29% |
| 2019 Q4 | - JPY | -100.0% |
| 2019 Q3 | 7 Million JPY | 120.59% |
| 2019 Q1 | 109 Million JPY | 0.0% |
| 2019 Q2 | -34 Million JPY | -131.19% |
| 2019 FY | 184.03 Thousand JPY | 100.24% |
| 2018 Q1 | - JPY | 0.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2018 Q2 | - JPY | 0.0% |
| 2018 FY | -78 Million JPY | -2.67% |
| 2018 Q4 | - JPY | 0.0% |
| 2017 Q1 | 18 Million JPY | 2.04% |
| 2017 FY | -75.96 Million JPY | 24.65% |
| 2017 Q2 | 5.89 Million JPY | -67.24% |
| 2017 Q4 | - JPY | 0.0% |
| 2017 Q3 | - JPY | -100.0% |
| 2016 Q2 | 18.65 Million JPY | 2.23% |
| 2016 FY | -100.81 Million JPY | -16136.31% |
| 2016 Q4 | 17.64 Million JPY | 26.49% |
| 2016 Q3 | 13.94 Million JPY | -25.25% |
| 2016 Q1 | 18.25 Million JPY | -4.95% |
| 2015 Q2 | 36.93 Million JPY | 111.1% |
| 2015 Q4 | 19.2 Million JPY | 26.84% |
| 2015 Q3 | 15.13 Million JPY | -59.01% |
| 2015 Q1 | 17.49 Million JPY | 0.0% |
| 2015 FY | -620.92 Thousand JPY | -100.27% |
| 2014 FY | 230.76 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -620.048% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -3481524.758% |
| SQZ Biotechnologies Company | 9.79 Million USD | -1002.716% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -822.604% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 9.326% |
| Mesoblast Limited | -35.16 Million USD | 407.097% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 316351.83% |
| Genus plc | 178.7 Million USD | 39.564% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -26230.867% |
| Marizyme, Inc. | 457.7 Thousand USD | -23496.139% |
| ContraFect Corporation | -154 Thousand USD | 70229.87% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 981918.182% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 216100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -140596.447% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -164213.535% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 27970.896% |
| MultiCell Technologies, Inc. | 49.32 USD | -218978002.19% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -168.223% |
| EV Biologics, Inc. | 48.9 Thousand USD | -220758.896% |
| Q BioMed Inc. | -8988.00 USD | 1201702.136% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -282.233% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 700307.469% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 50.932% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -154185.714% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 87020.83% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -173460.891% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 2181036.995% |
| Arch Therapeutics, Inc. | -2439.00 USD | 4428144.28% |
| IMV Inc. | -962.29 Thousand USD | 11323.135% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -76768.327% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 110852.192% |
| GB Sciences, Inc. | -624.00 USD | 17307792.308% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 125640.522% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 98.572% |
| Halberd Corporation | -208.00 USD | 51923176.923% |
| Enzolytics Inc. | 30.7 Thousand USD | -351599.883% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -7857.894% |
| SYBLEU INC | 11.69 Thousand USD | -923292.613% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -22286.528% |
| argenx SE | 1.1 Billion USD | 90.257% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 518.637% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -17393.165% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 73.63% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 1219612.195% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -143.475% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 9560.638% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -10831.384% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -1023.712% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 128902.967% |
| BioStem Technologies, Inc. | 15.42 Million USD | -600.169% |
| ONE Bio Corp. | 20.12 Million USD | -436.634% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 912647.529% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 223892.453% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -61069.008% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -61069.008% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 21090.846% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | 17239.103% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 372513.793% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -23897.707% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 33902.076% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -2243.75% |
| Bioxytran, Inc. | -8285.00 USD | 1303660.652% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 29054.424% |
| Neutra Corp. | 14.33 Thousand USD | -753300.767% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 131807.317% |
| PureTech Health plc | -1.6 Million USD | 6837.367% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 10886.668% |
| IXICO plc | 3.27 Million USD | -3202.752% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 15661.96% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 6130.151% |
| CSL Limited | 7.7 Billion USD | 98.598% |
| Cellectis S.A. | 18 Thousand USD | -599900.0% |